BIIB033
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for BIIB033, covering 2016-06-30 to 2022-04-28. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) [Phase 2]